Dhampur Bio Organics reported a consolidated net profit of ₹36.79 crore for the quarter ended June 30, 2026, a significant turnaround from the net loss of ₹22 crore in the corresponding period of the previous year. This recovery was driven by a one-time gain from the sale of a manufacturing unit and robust revenue growth across its continuing operations. The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter on July 14, 2026.

Financial Performance

The company's consolidated revenue from operations for Q1FY27 stood at ₹918.56 crore, up from ₹750.64 crore in the same quarter last year. Total income from operations, including other income, rose to ₹919.77 crore. On a standalone basis, revenue from operations increased to ₹939.55 crore from ₹788.15 crore in the previous year.

A key factor contributing to the profitability was the gain from the sale of the Meerganj sugar manufacturing unit. The company sold the undertaking on a slump sale basis for an aggregate consideration of ₹305 crore, resulting in a gain of ₹63.89 crore. This operation has been classified as discontinued operations.

Segment and Operational Details

The company operates across three main segments: Sugar, Bio Fuels & Spirits, and Country Liquor. The Country Liquor segment was the top revenue contributor, generating ₹489.08 crore in the quarter. The Sugar segment reported revenue of ₹371.32 crore, while Bio Fuels & Spirits contributed ₹80.78 crore.

The Board also approved the appointment of M/s Grant Thornton Bharat LLP as the Internal Auditor for the financial year 2026-27. The statutory auditors, Mittal Gupta & Co., performed a limited review of the unaudited financial results and issued an unmodified conclusion. The company noted that sugar is a seasonal industry, and quarterly performance may not be representative of the annual results.

Dhampur Bio Organics has completed the acquisition of a 74% stake in DBION Private Limited, formerly known as Sonitron Chemicals Private Limited, for a total consideration of ₹74,000. This strategic move, executed on July 09, 2026, transforms DBION Private Limited into a subsidiary of Dhampur Bio Organics and establishes it as a joint venture company under an agreement with Orgonew Private Limited.

Transaction Details

The acquisition involved the purchase of 7,400 equity shares at a rate of ₹10 each. This transaction represents 74% of the paid-up equity share capital of DBION Private Limited. The deal was structured in accordance with the Joint Venture Agreement entered into with Orgonew Private Limited.

Strategic Implications

With this acquisition, Dhampur Bio Organics secures a controlling interest in DBION Private Limited. The entity will now function as a subsidiary and a joint venture, allowing the acquirer to exercise significant influence over its operations and strategic direction. The completion follows prior board approvals on April 20, 2026, and May 30, 2026.